ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for E…

2024 ASH Annual Meeting Insights Hub

J. Schaefer

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

Pulmonary Embolism: Role of Catheter-Based Interventions

Baylor College of Medicine

P. Loyalka

Current Treatment Guidelines for ITP: Individualized Therapy and Eme…

Irina Murakhovskaya

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

Thrombophilia Screening: Best Practices and Who Should Be Tested

COR2ED The Heart of Medical Education

S. Middeldorp, J. Connors

Management of Treatment-Naive ITP Patients

Weill Cornell Medicine Oncology & Hematology

J. Bussel

ASH 2024 Review: Advances in VTE and Cancer-Associated Thrombosis

Cleveland Clinic Taussig Cancer Institute

K. Sanfilippo

Anemia and Thrombocytopenia Basics

UNC Lineberger Comprehensive Cancer Center

N. Vogler

Recent Advances in Classical Hematology

Indy Hematology Review

R. Brodsky

Key Insights on the FDA Approval of Marstacimab for Hemophilia

Akshat Jain

The Role of Complement in Disease: Focus on PNH, aHUS, CAPS, and CAD

Ilene Weitz